ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
'First-in-man' Clinical Trials Guideline Released For Public Consultation, Europe
The European Medicines Agency's Committee for Medicinal Products for
Human Use (CHMP) has adopted a draft guideline on requirements for
first-in-man clinical trials for potential high-risk medicinal products.
The draft guideline is being released for a two-month
public-consultation period.
Following extensive review and discussion of the very serious adverse
reactions that occurred during the first-in-man clinical trials of
TGN1412, national competent authorities in the EU Member States,
together with the EMEA and the European Commission, decided to produce
this Community guideline as one of the measures for minimising the risk
of such serious adverse reactions occurring.
The guideline has been prepared by experts in clinical trials and
non-clinical research from the national competent authorities and CHMP
working parties. It builds on principles laid down in European
legislation and existing guidelines.
The focus of this new draft guideline is on potential high-risk
medicinal products, i.e. products where the mode of action, the nature
of the target in the human body or the limited relevance of animal
models for the prediction of pharmacological or toxicological effects in
humans raises concerns that serious adverse reactions may occur.
The draft guideline gives guidance on managing the transition from
non-clinical studies, e.g. studies in animals or in vitro studies, to
first tests in humans for the abovementioned type of products. It covers
quality, non-clinical and clinical aspects, including the calculation
for the first doses to be given to human subjects, the initial
dose-escalation trials and the management of risk.
Following the conclusion of the two-month consultation period, a meeting
will be held at the EMEA with key stakeholders (European Commission,
national competent authorities, pharmaceutical industry, patients' and
healthcare professionals' organisations, academia and learned societies)
to consider the feedback received and to finalise the guideline for
publication thereafter.
1. The aim of the first-in-man clinical trials guideline is to
provide a common approach across EU Member States to the design and
conduct of first-in-man clinical trials of potential high-risk medicinal
products. The draft guideline can be found
here (PDF). Comments are
invited by 23 May 2007, and should be submitted using the template
available
here.
2. A Community guideline is a document considered to provide advice
to sponsors, applicants or marketing authorisation holders, national
competent authorities and/or other interested parties on the best way to
fulfil an obligation laid down in the Community pharmaceutical
legislation. Scientific guidelines are Community guidelines that relate
to specific scientific issues and reflect a harmonised EU approach,
based on the most up-to-date scientific knowledge. Guidelines are not
binding. Sponsors may deviate from the recommendations of the guideline
provided they can substantiate their approach.
3. Clinical trials are undertaken to allow data on the safety and
efficacy of new medicinal products to be collected. The first-in-man
trial is the initial step of the clinical development of a medicine in
humans and is part of the Phase-I or early-development clinical trials.
Phase-I trials are designed to look at the initial safety and
tolerability, as well as the pharmacology and pharmacokinetics of the
medicinal product concerned. Studies in this phase of development
usually have non-therapeutic objectives and may be conducted in healthy
volunteer subjects.
4. Clinical trials are regulated by European Union Directive
2001/20/EC, of 4 April 2001. The Directive harmonises across EU Member
States the administrative provisions governing clinical trials, as well
as the standards of good clinical practice (GCP) and good manufacturing
practice (GMP) to which they are conducted. It is the responsibility of
national competent authorities to assess applications to conduct
clinical trials with medicinal products.
EMEA
http://www.emea.europa.eu
"Prima-în-om-Studii clinice orientare eliberate pentru consultare publicã, Europa - 'First-in-man' Clinical Trials Guideline Released For Public Consultation, Europe - articole medicale engleza - startsanatate